Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 study of CNM-Au8 in patients with Multiple Sclerosis who are experiencing progression independent of relapse activity

Next Previous
Trial Profile

A phase 3 study of CNM-Au8 in patients with Multiple Sclerosis who are experiencing progression independent of relapse activity

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CNM Au8 (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use

Most Recent Events

  • 25 Apr 2023 Results presented in the Clene media release.
  • 25 Apr 2023 According to Clene media release, results from this study were presented in plenary sessions at the 2023 American Academy of Neurology (AAN) Annual Meeting taking place in Boston. These findings support the advancement of clinical development of CNM-Au8 in this study.
  • 22 Aug 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top